Nature communicationsOct 16, 2025

Using virus-like fatty molecules to deliver genetic material into cartilage for osteoarthritis treatment

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

A virus-inspired lipopeptide nanoparticle platform improved cartilage RNA delivery and reduced -like cartilage damage in mice.

Evidence

This formulation and preclinical platform study screened lipopeptide nanoparticles in vitro, found VPN-2 produced about 2.5-fold higher transfection than conventional lipid nanoparticles, and tested a ROS-responsive nano-in-gel system in surgical ACTL and PTOA mouse models.

Caveat

The therapeutic evidence is limited to engineered delivery assays and mouse osteoarthritis models, with no human cartilage or clinical outcome data.

Simplified

Cartilage-targeted gene therapy is promising for (OA) treatment, though its potency critically depends on the effectiveness of delivery vectors. Here, we modularly develop a series of non-pathogenic, virus-inspired lipopeptide-based nanoparticles (VPN) tailored to deliver nucleic acids to cartilage. The cationic moiety of lipopeptide with variable arginine and histidine residues is the key functional component, and screened by in vitro performance. The optimized VPN-2 with a moiety of -[(R)-(H)]- facilitates sufficient endocytosis and effective lysosomal escape, achieving about 2.5-fold improvement in transfection potency over conventional lipid nanoparticles. To address the tradeoff between penetration and retention within articular cartilage, si-VPN-2 is further formulated into ROS-responsive nano-in-gel system, which turns out to alleviate cartilage degeneration in surgical ACTL mice, and further synergizes with methylprednisolone to implement superior joint protection in PTOA mice. Our study underscores the platform's potential of VPN as cartilage-targeted RNA delivery vector for innovative OA therapy. 5 4 2

Key numbers

2.5×

Transfection Potency Increase

VPN-2 shows 2.5× better transfection potency than conventional lipid nanoparticles.

~75%

MMP-13 Expression Reduction

treatment results in ~75% reduction of MMP-13 expression in vivo.

21 days

Intra-articular Retention Duration

maintains intra-articular retention for over 21 days.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 15

authors report competing interests

15 report none

PubMed

Using virus-like fatty molecules to deliver genetic material into cartilage for osteoarthritis treatment

Abstract

Key numbers

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief

Abstract

Key numbers

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief